Osiris Therapeutics (OSIR) Posts Q2 Loss of 11c/Share
Tweet
Share
E-mailGet Alerts OSIR Hot Sheet
Price: $18.99 --0%
Financial Fact:
Total operating expenses: 19.63M
Today's EPS Names:
MAYS, CRMT, REPL, More
Financial Fact:
Total operating expenses: 19.63M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Osiris Therapeutics (NASDAQ: OSIR) reported Q2 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $5.29 million versus the consensus estimate of $4.35 million.
For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.
For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
- UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
